Abstract
Aims Although ventricular dysfunction is associated with adverse outcomes in cardiac sarcoidosis (CS), the potential role of atrial function is unknown. The aim of this study was to assess the effect of atrial function on clinical outcomes in patients with CS.
Methods We retrospectively enrolled 96 patients with CS. Left atrial (LA) and right atrial (RA) function was calculated as LA global longitudinal strain (LAGLS) and RA global longitudinal strain (RAGLS), respectively, using two-dimensional speckle-tracking echocardiography. Major adverse cardiac event (MACE) was a composite of cardiac death, fatal ventricular arrhythmia events, and hospitalization for heart failure.
Results During a median follow-up of 6.0 years, 37 patients had MACE. LAGLS and RAGLS were lower in patients with MACE than in those without MACE. Kaplan-Meier curves showed that patients with atrial dysfunction with LAGLS of ≤ 19.6% or RAGLS of ≤ 22.3% had a higher rate of MACE than those without atrial dysfunction (log-rank test, p = 0.01 for both comparisons). The presence of LAGLS of ≤ 19.6% or RAGLS of ≤ 22.3% was significantly associated with MACE in a model that included age, sex, and New York Heart Association class (hazard ratio: 2.19, 95% confidence interval: 1.06–4.55, p = 0.04; hazard ratio: 2.27, 95% confidence interval: 1.07–4.85, p = 0.03, respectively).
Conclusions Atrial dysfunction represented by LAGLS and RAGLS is associated with adverse outcomes in patients with CS. Our findings suggest a potential role of atrial function for predicting the prognosis in CS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None declared.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
None declared.
